ABHD8 include a range of compounds that primarily function by manipulating intracellular levels of cyclic AMP (cAMP), a second messenger that often leads to the activation of protein kinase A (PKA), which can then phosphorylate and activate ABHD8. Forskolin directly stimulates adenylyl cyclase, the enzyme responsible for the synthesis of cAMP, thereby raising cAMP levels and engaging PKA signaling that targets ABHD8. Analogously, Forskolin Analog operates by the same mechanism, binding to adenylyl cyclase and enhancing cAMP synthesis, which in turn activates PKA and likely promotes the activation of ABHD8. PDE inhibitors like IBMX and Rolipram contribute to elevated cAMP levels by preventing the degradation of cAMP, with IBMX acting non-specifically across phosphodiesterase (PDE) isoforms, and Rolipram selectively targeting PDE4. This accumulation of cAMP can activate PKA, which then may act on ABHD8. Sildenafil and Zaprinast, while traditionally known for inhibiting PDE5, can also cause a rise in cAMP levels that may translate into increased PKA activity and subsequent ABHD8 activation.
Isoproterenol, a beta-adrenoceptor agonist, and Glucagon, through its G protein-coupled receptor, both stimulate adenylyl cyclase, leading to the production of cAMP and activation of PKA, which is likely to affect ABHD8 activation. PGE1, interacting with its E-prostanoid receptors EP2 and EP4, similarly results in increased cAMP and engages PKA, which can phosphorylate ABHD8. Milrinone, targeting PDE3, also raises cAMP levels, contributing to a cellular environment that fosters PKA-mediated ABHD8 activation. Furthermore, ABHD8 activation is also considered in the context of lipid signaling molecules, as exemplified by Anandamide, an endocannabinoid that may directly interact with ABHD8's hydrolase function and modify its activity. The collective action of these chemicals enhances cAMP levels in the cell, either by promoting its production or by inhibiting its degradation, which in turn activates PKA. This activation cascade is critical for the phosphorylation and functional activation of ABHD8.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specifically inhibits phosphodiesterases, increasing cAMP levels, which may lead to ABHD8 activation via PKA-mediated phosphorylation pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selectively inhibits PDE4, causing an increase in cAMP which may activate ABHD8 through PKA-dependent phosphorylation. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Inhibits PDE3 and increases cAMP levels, indirectly leading to the potential activation of ABHD8 through PKA-dependent phosphorylation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenoceptor agonist that increases intracellular cAMP, potentially leading to the activation of ABHD8 through PKA-dependent phosphorylation. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Through its receptor EP2/EP4, it increases cAMP levels, which can result in the activation of ABHD8 via PKA-dependent phosphorylation. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Inhibits PDE5 and possibly PDE9, leading to increased cAMP levels, which may result in the activation of ABHD8 through PKA-dependent pathways. | ||||||